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Introduction:  Pregnancy-associated plasma protein A (PAPP-A) is a marker of plaque instability in acute coronary syndromes (ACS) and is 
released during atherosclerotic plaque disruption. PAPP-A is detectable in the plasma in both a free form and as a complex bound to the proform 
of eosinophil major basic protein (proMBP). Recently, a new ELISA-based assay has been developed that is specific for the free circulating protein 
(cPAPP-A) which is the form released during plaque disruption, whereas prior assays have measured both the free and complexed forms, possibly 
leading to false positive information. We assessed the hypothesis that measuring plasma cPAPP-A levels using this novel assay may identify patients 
with ACS.
Methods: We measured plasma cPAPP-A levels in three patient cohorts: normal subjects (control) with no evidence of atherosclerosis on coronary 
angiography (n= 25), subjects with stable coronary artery disease (CAD), defined as at least one lesion of ≥50% stenosis on coronary angiography 
(n=28), and patients presenting with ACS including patients presenting with unstable angina or myocardial infarction (n=24).
Results: The mean values of plasma cPAPP-A were 3.05 ± 0.50, 4.48 ±0.76, and 9.05±3.02 for the control, stable CAD and ACS groups, 
respectively. Plasma levels of cPAPP-A were significantly higher in the ACS group compared with controls. At a threshold value of 3.58, plasma 
cPAPP-A levels identified patients with ACS with a sensitivity of 0.63 and a specificity of 0.79 (P=0.01). Plasma cPAPP-A levels however did not 
discriminate between stable CAD patients and normal subjects in this cohort of patients (P=0.19).
Conclusions: A new free circulatory PAPP-A assay (cPAPP-A) that measures the cardiac source of the protein has potential to identify ACS patients 
in this pilot study but further studies with larger populations will be needed to more accurately address the sensitivity and specificity of this new 
assay. Measurement of this protein may add to the diagnosis and prognosis of patients with CAD.
